Our meta-analysis included 4 studies, indicating that the elevated plasma level of CRABP2 significantly predicted poor OS (HR: 1.14 (95% CI: 1.00–1.30, Fig. 1) in lung cancer patients. The gene discussed is CRABP2; the disease is lung carcinoma.